INTRODUCTION
Hemodynamic, cardiac, and renal alterations are prominent manifestations of hyperthyroidism (9, 25). The hyperthyroid state courses with hyperdynamic circulation characterized by increased cardiac output, heart rate, pulse pressure and decreased peripheral resistance (9, 25).
The administration of thyroxine to rats produces dose-related increases in blood pressure (16, 25) , cardiac and renal hypertrophy, proteinuria, and a decreased renal ability to excrete sodium after several stresses (16, 20, 25) .
NO can be produced by the enzymatic activity of a family of three nitric oxide synthase (NOS) isoforms: neuronal (nNOS), inducible (iNOS), and endothelial (eNOS). These NOS isoforms are present in tissues primarily related to cardiovascular regulation and in the kidney (23) . Our group recently observed that administration of the nonspecific nitric oxide inhibitor, N F -nitro-L-arginine methyl ester(L-NAME), at a dose without pressor activity in normal rats, or administration of the iNOS inhibitor, aminoguanidine, increased BP in thyroxine-treated rats (20, 21) . However, the effects of nNOS blockade in the cardiovascular manifestations of hyperthyroidism have not been investigated.
Nitrogen heterocyclic compounds represent an important group of NOS inhibitors that bind at the sixth co-ordination position of the heme-iron atom (31) . Thus, it has been demonstrated that indazole derivatives and specially 7-nitroindazole (7NI) are potent nNOS inhibitors (14, 28, 31, 32) . 7NI is more selective for nNOS than methyl-or nitro-argininebased inhibitors, and the administration of this indazole agent to experimental animals inhibits nNOS in the brain without changes in blood pressure or endothelium-dependent relaxation (2, 11, 32) . Moreover, 7NI has been used as an effective nNOS blocker in many different experimental settings, including studies of renal function (1, 3, 30) , learning (13) or penile erection (22) .
4
Several studies have demonstrated an important role for nNOS in central and peripheral modulation of sympathetic activity and in the regulation of drinking behavior (18). Thus, 7NI inhibited the sympathoexcitatory cardiovascular response produced in several circumstances (5, 6, 24) and it also inhibited the increase in plasma vasopressin (AVP) produced by salt loading in rats (26).
Because the cardiovascular manifestations of hyperthyroidism are suggestive of an increased sympathetic activity (10) and are associated with polydipsia and polyuria (8) we hypothesized that nNOS may participate in these alterations. With this background, we analyzed the effects of the chronic nNOS blockade with 7-NI on the long-term control of BP and other variables in hyperthyroid rats.
METHODS

Animals
Forty eight male Wistar rats born and raised in the experimental animal service of the University of Granada were used. The experiment was performed according to European Union guidelines for the ethical care of animals. Rats initially weighing 280±4 g were randomly assigned to the different experimental groups. Each experimental group comprised eight animals, except where stated. All rats had free access to food and tap water. 7NI (30 mg/kg/day) was given by gavage because of the low solubility of this compound. Thyroxine (Merck) was dissolved in isotonic saline plus 0.5 N NaOH (1/100 v/v), buffered to pH 7 and s.c. injected. The doses of T 4 and of 7NI are in accordance with previous protocols used in our laboratory (16, 29) .
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Experimental protocols
Experiment I. Effects of chronic administration of 7NI to hyperthyroid rats. The groups were: control, 7-nitroindazole (7NI), thyroxine at 50 (T 4 50) or 75 (T 4 75) µg/rat/day and thyroxine treated rats at 50 and 75 µg/rat/day plus 7-nitroindazole (T 4 50+7NI and T 4 75+7NI) rats. The treatments were administered for four weeks. Body weight (BW), tail systolic BP (SBP), and heart rate (HR) were measured once a week. Tail SBP and HR were measured with the use of tail-cuff plethysmography in un-anesthetized rats (LE 5001-Pressure Meter, Letica SA, Barcelona, Spain). When the experimental period was completed, all rats were housed in metabolic cages (Panlab, Barcelona, Spain) with free access to food and water and to their respective treatments for four days (two days for adaptation + two experimental days), in order to measure the food and water intake and collect urine samples. Twenty-four-hour urine volume, proteinuria, creatinine, and total excretion of sodium and potassium were measured. The mean values of all intake and urinary variables obtained during the two experimental days were used for statistical analyses among the groups.
After completion of the metabolic study, the rats were anesthetized with ethyl ether. A polyethylene catheter (PE-50) containing 100 units of heparin in isotonic sterile NaCl solution was inserted into the femoral artery for intra-arterial BP and HR measurement in conscious rats and for extraction of blood samples. The catheter was tunneled subcutaneously and brought out through the skin at the dorsal side of the neck. Intra-arterial BP was measured at 24 h after implantation of the femoral catheter. Direct BP and HR were recorded continuously for 60 min with a sampling frequency of 400/s (McLab, AD Instruments, Hastings, UK). The values obtained during the last 30 min were averaged to obtain the BP and HR values used for inter-group comparisons. Subsequently, blood samples taken with the femoral catheter were used to determine total protein, electrolytes, and creatinine concentration. Finally, the rats 6 were killed by exsanguination. The kidneys and ventricles were then removed and weighed.
The heart was divided into right ventricle and left ventricle plus septum.
Experiment II. Expression of nNOS was determined by western blot in the hypothalamus of hyperthyroid (T 4 75) rats treated for four weeks and in control rats (n= 4, each). Hypothalami were homogenized and centrifuged at 12000 g for 5 min at 4 ºC. 30 µg of proteins from the supernatant were subjected to SDS-PAGE using 4 to 7.5 % gels. After electrophoresis, proteins were transferred to a nitrocellulose membrane. The membrane was stained with Ponceau stain, which verified the uniformity of protein load and transfer efficiency across the test samples. After blocking, the membrane was probed with rabbit anti-nNOS polyclonal antibody (BD Biosciences, Erembodegen, Belgium). Bound antibodies were detected with a secondary horseradish peroxidase-conjugated goat anti-rabbit antibody (BD Biosciences, Erembodegen, Belgium). The bands were visualized using the enhanced chemiluminiscence system ECL Plus (Amersham, Buckinghamshire, UK) and chemiluminiscence intensity was quantified by a Kodak Image Station (Kodak, Newhaven, CT).
Experiment III. This experiment was performed to evaluate the contribution of sympathetic activity to arterial blood pressure and heart rate in hyperthyroid and hyperthyroid-7NI treated rats. The acute blood pressure and heart rate responses to an i.v. injection of the sympathetic blocker pentolinium (Sigma, 10 mg/kg) were analyzed in conscious control, T 4 75 and T 4 75+7NI rats. After four weeks of treatment, the femoral artery and vein were catheterized, allowing a 24h recovery period to perform the experiment. The dose of pentolinium selected was previously reported (19) to produce maximal sympathetic inhibition.
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Analytical procedures
Proteinuria was measured by the method of Bradford (4). Plasma and urinary electrolytes, plasma protein, and creatinine were measured in an autoanalyzer (Beckman CX4, Breca, CA, USA).
Statistical analysis
The evolution of SBP and HR with time was compared with the use of a nested design, with groups and days as fixed factors and rat as random factor. When the overall difference was significant, Bonferroni's method with an appropriate error was used. Comparisons of each variable at the end of the experiments were done by performing a one-way ANOVA. When the overall ANOVA was significant, we performed pairwise comparisons using Bonferroni's methods. The differences were considered significant when P<0.05. The western blot data and the acute responses to pentolinium were analyzed using unpaired Student's t-test.
RESULTS
Blood pressure and heart rate
The left-hand graphs in Figure 1 show the time course of the tail SBP and HR and the righthand graphs show the final SBP and HR measured by direct recording in the experimental groups. T 4 administration produced a dose-related increase in SBP and HR and in final SBP, HR and PP when compared with control rats. 7NI administration to normal rats at the dose used in this experiment did not modify the time course evolution of BP, HR, final SBP, HR, or PP. However, 7NI administration to hyperthyroid rats reduced BP, HR, and PP in both T 4 -treated groups. Thus, the T 4 50+7NI group showed a similar SBP and HR evolution and final SBP, HR, and PP to those of control rats and these variables were significantly attenuated in the T 4 75+7NI group. PP values in the groups were: control, 36.8±1.6; 7NI, 34.9±1.6; T 4 50, 
Morphological variables
All T 4 -treated groups showed a significant reduction in body weight compared with the control groups. Kidney-to-body weight ratios and left ventricular-to-body weight ratios were significantly increased in T 4 50 and T 4 75 groups in comparison with controls. The left ventricular-to-heart weight ratio was not significantly modified in T 4 -treated groups in comparison with controls. None of these morphologic variables were affected by 7NI treatment in control or T 4 -treated rats (Table 1) .
Plasma, metabolic, and urinary variables
There were no significant differences in plasma sodium and potassium among the groups.
Total plasma protein concentration was decreased in both T 4 groups, and 7NI administration reversed these decreases and did not significantly modify this variable in control rats. Plasma urea and creatinine were increased in the T 4 75 group, and similar to controls in the T 4 75+7NI group (Table 2) .
Metabolic studies at the end of treatment showed increased food and fluid intake (g/100 g body weight) in all T 4 -treated groups in comparison with controls. Food intake was significantly reduced in the T 4 75+7NI group when compared with the T 4 75 group. The 7NI group showed increased fluid intake versus controls. However, 7NI administration produced a reduction in water intake in both T 4 treated groups. Thus, T 4 50+7NI and T 4 75+7NI groups showed a significantly reduced water intake when compared with their respective T 4 -treated groups (Table 3) .
Water and sodium balances, proteinuria, and creatinine clearance (CrC) values are summarized in Table 4 . Water and sodium balances significantly increased in both T 4 -treated 9 groups, whereas signification was not reached in the T 4 -7NI treated groups when compared with controls. 7NI administration reduced diuresis in both T 4 treated groups. Total sodium and potassium excretion was higher in the T 4 -treated animals. These data are consistent with the greater food intake of T 4 -treated rats. 7NI did not significantly affect natriuresis or kaliuresis in control or T 4 -treated groups (data not shown). Proteinuria was significantly increased in all T 4 -treated groups and was unaffected by 7NI treatment. However, 7NI produced a mild increase in proteinuria in control rats. Creatinine clearance normalized per g kidney weight was similar in all experimental groups, with the exception of a lower value in the T 4 75 group.
Hypothalamic nNOS expression
Hypothalamic nNOS expression was higher in hyperthyroid rats than in control rats ( Figure   3 ). 
Blood pressure response to ganglionic blockade
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DISCUSSION
This study shows that hyperthyroid rats had an increased hypothalamic nNOS expression and that the administration of the nNOS inhibitor 7NI prevented or attenuated the BP, HR and PP increases produced by increasing doses of thyroxine. Moreover, 7NI administration attenuated the increased food intake and polydipsia of hyperthyroid rats in this study.
Therefore, our results suggest that nNOS may participate in developing the characteristic manifestations of hyperdynamic circulation and in the food and fluid intake behavior of hyperthyroid rats. The hemodynamic data clearly contrast with previous studies from our laboratory showing that the nonspecific blockade of NOS activity with L-NAME (20) or the specific blockade of iNOS with aminoguanidine (21) aggravates the time-course of hypertension in hyperthyroid rats. Taken together, these findings suggest that prohypertensive effects predominate after nonspecific NOS blockade, overriding the antihypertensive effects of nNOS blockade.
The mechanism by which chronic 7NI administration to T 4 -treated rats suppresses the cardiovascular manifestations of hyperthyroidism remains to be defined, but we propose the possibility that 7NI may produce a central or peripheral blockade of sympathetic discharge in these animals. In this regard, the data showed that the sympathetic blockade with pentolinium produced a greater BP decrease in hyperthyroid than in 7NI treated or control rats, suggesting a reduced contribution of the sympathetic tone in the resting blood pressure of hyperthyroid rats treated with 7NI. Moreover, a number of studies have demonstrated an important role for nitric oxide in central and peripheral modulation of sympathetic activity. Thus, microinjection of 7NI bilaterally into the rostral ventrolateral medulla of rat, where sympathetic vasomotor tone originates, produced a reduction in systemic BP and HR and in the power density of the vasomotor components in the spectrum of arterial BP signals, which is the experimental Page 10 of 28 index of sympathetic neurogenic vasomotor tone (6) . 7NI administration also inhibited the sympathoexcitatory cardiovascular response produced during intoxication by the cholinesterase inhibitor mevinphos, which was accompanied by increased nNOS mRNA levels in the rostral ventrolateral medulla (5). Furthermore, 7NI inhibited the reflex sympathetic pressor response to bradykinin (24) . Additionally, indazole derivatives and the V 2 -adrenergic agonist, clonidine, are structurally similar. Based in this observation, Venturini et al. (27) analyzed clonidine as a nNOS inhibitor, and reported that this drug competitively inactivated nNOS, without affecting iNOS or eNOS activities in vitro. Clonidine inhibits central sympathetic activity, reducing BP and HR, effects that resemble those produced by 7NI in hyperthyroid rats.
Another possible explanation for the antihypertensive effects of 7NI in hyperthyroid rats is its action on water and sodium handling, probably mediated by an increased renal sympathetic tone. Thus, water and sodium balances were significantly increased in both T 4 -treated groups, whereas the comparison between T 4 -7NI treated groups and controls did not reach significance. These results suggest that 7NI treatment attenuates these positive balances, which might contribute to its antihypertensive effect in hyperthyroid rats.
The absence of changes in BP or HR after chronic administration of 7NI to control rats is consistent with previous observations in rats and mice. Chronic administration of 7NI did not modify BP or HR in normal, sensitized saline-drinking, or DOCA-treated rats (29) , or in male or female rats studied in different experimental settings (1, 3) . Moreover, absence of the gene for the neural isoform of NOS had no effects on the BP of knockout mice (17). Taken together, all these data indicate that the hemodynamic effects of 7NI administration (nNOS blockade) in hyperthyroid rats are not due to nonspecific antithyroid effects of this drug.
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Results show that ganglionic blockade produces a similar decrease in MAP in hyperthyroid and control rats and an increase in HR in hyperthyroid rats, whereas it did not change HR in control rats. These data are similar to those reported by Foley et al (7) in hyperthyroid rats after ganglionic blockade with trimethaphan. These authors suggest that the increase in HR induced by the autonomic blockade indicates an increased parasympathetic influence on this variable in hyperthyroid rats, which may be a compensatory response against the direct stimulating effects of thyroid hormones on HR. In any case, our results in the T 4 75+7NI
clearly indicate a reduced sympathetic contribution to resting MAP, as reported above, despite the increased in HR induced by the ganglionic blockade.
One critical issue in this study concerns the specificity of 7-NI as an inhibitor of nNOS.
Several studies have indicated that 7NI selectively inhibits nNOS without affecting eNOS or iNOS (2, 11, 32) . In fact, 7-NI was able to block more than 80% of NOS activity in the cerebellum, a region with the highest levels of NOS in the central nervous system, without altering BP (2, 14, 15) . Moreover, many laboratories have reported that acute and chronic 7NI administration to normal rats did not affect BP or endothelium dependent vasodilatation (1, 3, 11, 14, 29) , although Zagvadin et al. (33) observed a pressor response after 7NI administration (50 mg/kg i.p.) to conscious rats. Other studies indicate that 7NI has little effect on iNOS (32) . Thus, 7NI produced greater inhibition of nNOS than of iNOS in lung cells (15) and renal medulla (12) of rats.
The 7NI group showed a mild polyuria-polydipsia syndrome, in agreement with previous observations by our group (29) . This phenomenon has been attributed to an inhibitory effect of 7NI on the release of AVP, because nNOS and AVP are colocalized in the supraoptic and paraventricular nuclei (18) and other forebrain structures that participate in the regulation of drinking behavior. In fact, the systemic administration of 7NI was recently shown to inhibit the increase in plasma AVP produced by salt loading in rats (26). However, 7NI administration to hyperthyroid rats produced a decreased fluid intake. We lack a reasonable explanation for this last result, but it is consistent with the inability of 7NI to increase fluid intake in saline-drinking or deoxycorticosterone-treated rats (29) .
Hyperthyroidism produces cardiac hypertrophy (9, 20, 25). However, the left ventricular-toheart weight ratio, an index of absolute left ventricular hypertrophy, was not affected by T 4 treatment, indicating that cardiac hypertrophy in hyperthyroidism involves both ventricles as previously reported (20) . 7NI treatment did not modify either ratio in the hyperthyroid groups, despite its antihypertensive effect. These data confirm previous findings (16, 20) indicating that ventricular hypertrophy in hyperthyroidism is unrelated to the BP level.
Total plasma protein concentration is decreased in hyperthyroid rats, which is an index widely used, indicating intravascular volume expansion. This alteration is in agreement with previous findings by our group (20) and may be related to the positive water and sodium balances of these animals. Plasma protein concentration was significantly increased by 7NI treatment in hyperthyroid rats. The basis for this effect is not clear, although the ability of 7NI to reduce plasma urea and creatinine levels and creatinine clearance and to attenuate the positive water and sodium balances in hyperthyroid rats indicates that this drug may improve renal function and therefore blood volume, suggesting the possible participation of nNOS in the renal dysfunction of these animals.
The proteinuria observed in the present T 4 -treated rats was not affected by 7NI treatment, despite its antihypertensive effect. However, the administration of 7NI to normal rats unexpectedly increased proteinuria. These observations agree with previous reports that the proteinuria of hyperthyroid rats is not related to BP levels (16, 20, 21 ).
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In conclusion, the present study shows that chronic 7NI treatment suppresses or attenuates the characteristic hemodynamic manifestations of hyperthyroidism, suggesting that nNOS contributes to developing the hyperdynamic circulation of hyperthyroidism. This study also demonstrates that 7NI administration attenuates the polyphagia and polydipsia of hyperthyroid rats and improves their glomerular filtration rate.
Perspectives
This paper shows that 7NI administration prevents hemodynamic and other characteristic manifestations of hyperthyroidism by a mechanism that is unrelated to a nonspecific antithyroid effect. The data reported herein indicate that nNOS participates in the pathophysiology of hyperthyroidism. To our knowledge, this is the first report that assesses the effects of the blockade of nNOS isoform on hemodynamic and renal abnormalities in hyperthyroidism, opening up a new line for the study of cardiovascular abnormalities in thyroid disorders. This study also suggests that 7NI may be of therapeutic value in the hyperthyroid state. 
